
Re-Tain® is ImmuCell’s new subclinical mastitis treatment for lactating dairy cows without a milk discard or meat withhold requirement. Sales of Re-Tain® are subject to FDA approval, which is projected to be 4Q2022. “Mark’s skillset and network couldn’t be better aligned with the primary objectives of this role,” indicated Bobbi Brockmann. “He will champion research and communication efforts aimed to bridge the value of Re-Tain® from producer to processor. I expect his veterinary experience and mentoring will make our commercial team even more robust and positively impact our First Defense line of scours prevention products, as well.”
Dr. Wustenberg worked privately as a dairy practitioner and consultant. Subsequent to that he held leadership roles at Tillamook County Creamery Association, including multiple vice presidencies advising sustainability, quality, operations, public relations and member services, plus he served as interim CEO for the farmer-owned cooperative based in Oregon. Dr. Wustenberg also worked with notable organizations, such as American Association of Bovine Practitioners, Dairy Marketing Incorporated, American Veterinary Medical Association, Northwest Food Processors Association, Oregon Cheese Guild and Oregon State Food Technology Department. In addition, he was part of the Monsanto Dairy Business team centering producers and processors around industry changing technologies.
Dr. Wustenberg lives in Bay City, Oregon, with his wife Judy, who also has served the dairy industry for many years as a nutritionist.
ImmuCell Corporation’s (Nasdaq: ICCC) purpose is to create scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is in the late stages of developing Re-Tain,® a novel treatment for subclinical mastitis in dairy cows without a milk discard requirement that provides an alternative to traditional antibiotics. Press releases and other information about the company are available at: http://www.immucell.com.

Be the first to comment